Dalton Einhorn

Dalton Einhorn has more than 20 years of experience in biopharmaceutical start-ups, life sciences venture capital, pharmaceutical commercial operations and investment banking. Most recently he has had several entrepreneurial roles including as a co-founder of an early-stage oncology therapeutics company and as an advisor to several emergent medical device and biotherapeutics companies. Prior to that, he was a venture capital investor for Johnson & Johnson Development Corporation and Latterell Venture Partners, and was an investor in Genocea Biosciences, Astute Medical and PowerVision, Inc., and a board member of ViaCyte, Inc. Prior to his venture capital career, Mr. Einhorn held a number of branded products marketing and global new product commercialization roles at Roche, Daiichi-Sankyo and Novo Nordisk, and he has an extensive background in valuation, forecasting and business modeling, as well as business development. He began his career in the Mergers and Acquisitions group of CS First Boston (now Credit Suisse). Mr. Einhorn has a B.A. from Drew University and an MBA from Yale University.